

News Release

FOR IMMEDIATE RELEASE

20 February 2011

Contact: **Neal G. Koller**
President & CEO
Board of Directors
+1 (443) 994-0101

LIFE SCIENCE INDUSTRY EXECUTIVE ELECTED TO PLUROGEN BOARD OF DIRECTORS

(Charlottesville, VA, 20 February 2011) – PluroGen Therapeutics, Inc. is pleased to announce that Daniel M. Brody has been elected to the PluroGen Board of Directors.

Mr. Brody joins PluroGen with a distinguished and successful career in life sciences, entrepreneurial business growth and board management. He is the Founder and CEO of Health Data Services, Inc., which has grown to become one of the country's premier medical practice management software and services companies and developer of MedLedger, an ONC-ATCB Certified Complete EHR.

Mr. Brody served on the Board of Directors and Executive Committee of Insmmed, Inc., (NASDAQ: INSM). He has also served on the Board of the Virginia Department of Medical Assistance (Virginia Medicaid) (1994-2002) and was its Chairman (1996-2000), the University of Virginia 2020 Strategic Planning Committee, the Learning Center of Virginia, the Charlottesville-Albemarle Community Foundation, and Congregation Beth Israel.

Mr. Brody is the Managing Partner of Greenwood Partners and an Adjunct Professor at the University of Virginia. Mr. Brody serves on the boards of Prolifiq Software, the Hillel Foundation at the University of Virginia, and the Foundation of Hillel International.

Mr Brody earned a B.A. in Economics from the University of Virginia and an MBA from New York University – Leonard N. Stern School of Business.

Neal G. Koller, President & CEO of PluroGen, commenting on Mr. Brody joining the PluroGen Board of Directors said "Mr. Brody's entrepreneurial success in building Health Data Systems will bring a unique and valued set of skills to the PluroGen Board. We are honored to have him accept our offer and look forward to working with him."

About PluroGen Therapeutics, Inc.

PluroGen is a burn, wound, and skin care company commercializing its multiple patent-protected technology platforms. The Company's primary platform is its core PluroGel® technology which provides paradigm-shifting, superior and differentiated physical, bio-impact, and multi-function products. PluroGel® is University developed and is in routine use at the University, having shown superior results on more than 10,000 patients in two different patient populations - severe burns and wounds. PluroGen's three technology platforms are configured to deliver a variety of medicinal and beneficial compounds covering the six key areas of treatment in tissue management and healing: 1. Cleansing; 2. Anti-Infection; 3. Reduced Pain; 4. Anti-Inflammation; 5. Tissue salvage; 6. Tissue regeneration.

PluroGen has a strong new product pipeline including PluroGel® Barrier Gels and Dressings, PluroGel® branded topical antimicrobial prescription products and PluroGel® co-branded products with select commercial partners.

PluroGen's senior management, operations team, boards and principal investigators are all recognized global commercial and clinical leaders in PluroGen's target markets of burn and wound care.

For more information about PluroGen Therapeutics, Inc., visit the Company's web site at www.plurogen.com.

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and which are identified from time to time in the Company's reports filed with the U.S. Securities and Exchange Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Information included on PluroGen Therapeutics, Inc website is not incorporated herein by reference or otherwise.